Diabetic Peripheral Neuropathy Treatment Market

Diabetes-related high blood sugar levels can result in a condition known as diabetic peripheral neuropathy (DPN), which damages the body's peripheral nerves. Controlling blood sugar levels with food, exercise, and medication is the main objective of DPN treatment. This may lessen the risk of ongoing nerve injury. Analgesics, antidepressants, and anticonvulsants are just a few of the drugs that can be used to treat DPN-related pain. Pain can be reduced by applying topical creams or patches containing capsaicin or lidocaine. TENS therapy uses electrodes that are applied to the skin to deliver mild electrical impulses to nerve terminals. Pain can be reduced by doing this.

Drivers:
The prevalence of diabetes is rising at an alarming rate worldwide. Over 60% of diabetics worldwide live, according to the International Diabetes Federation. The need for DPN treatment alternatives in the area is anticipated to rise as a result of the increased prevalence of diabetes. The expansion of the DPN treatment market is anticipated to be fueled by the creation of novel and cutting-edge treatment methods such as electrical nerve stimulation, gene therapy, and stem cell therapy.

Risks:
Particularly in wealthy nations, the cost of DPN treatment can be substantial, which may make it less accessible to patients who cannot afford it. The adverse effects of some DPN medications may make it more difficult for a patient to comply with therapy. Despite rising knowledge of diabetes and its associated consequences, many DPN patients might not be aware of their treatment alternatives, which could restrain market expansion.

Due to the increasing prevalence of diabetes in the region, the DPN therapy market in the Asia-Pacific region is anticipated to have substantial growth. Some of the factors causing the rise in diabetes prevalence in Asia and the Pacific include an aging population, sedentary lifestyles, and bad diets.

Several of the key players are Achelios Therapeutics, Immune Pharmaceuticals, Inc., Commence Bio, Inc., and Grunenthal GmbH.